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Purpose: Interleukin (IL)-1β, an inﬂammatory mol-
ecule, contributes to the development of atherothrom-
bosis and worsening of islet β-cell function.
Canakinumab, a human monoclonal antibody, targets
IL-1β–dependent inﬂammation and reduces the vas-
cular inﬂammatory biomarker, high-sensitivity C-re-
active protein (hsCRP), and other inﬂammatory
cardiovascular biomarkers. Here, we aimed to assess
the pharmacokinetic (PK) and pharmacodynamic
characteristics, including the effect on hsCRP, of
canakinumab in patients with type 2 diabetes mellitus
(T2DM) after a 2-hour single-dose intravenous
infusion.
Methods: This multicenter, randomized, double-
blind, placebo-controlled, dose-escalation study was
conducted in patients with T2DM (diagnosed Z6
months before screening) on a stable daily dose of
metformin. Patients were randomly assigned to receive
a single intravenous dose of canakinumab 0.03, 0.1,
0.3, 1.5, or 10 mg/kg or placebo. The study was
initially designed with 1 small cohort (15 patients, 0.3
mg/kg) on a stable dose of metformin Z500 mg/d for
an initial tolerability evaluation; all other patients
were on a stable dose of Z850 mg/d of metformin.
The PK proﬁle was assessed at 0 and 2 hours and at
days 2, 14, 28, 56, 84, and 168. Changes in hsCRP
and hemoglobin (Hb) A1c levels were assessed at
weeks 4, 8, 12, and 24.
Findings: Of the 231 enrolled patients, 222 com-
pleted the study. Median hsCRP values at screening
ranged from 1.8 to 3.2 mg/L, and the median daily
dose of metformin ranged from 1000 to 2000 mg.
Exposure to canakinumab was dose proportional. The
mean half-life ranged from 17 to 26 days, and mean
systemic clearance ranged from 0.094 to 0.128 mL/h/kg.November 2014Dose-related reductions in hsCRP were signiﬁcantly
greater with canakinumab compared with those with
placebo at week 4 (0.2 mg/L, 0.5 mg/L, 1.5 mg/L,
and 1.7 mg/L with the 0.1-, 0.3-, 1.5-, and 10-mg/kg
doses, respectively; all, P o 0.05). Signiﬁcant reductions
in hsCRP were maintained up to week 12 with the 2
highest doses of canakinumab (0.8 mg/L with 1.5 mg/
kg and 1.3 mg/L with 10 mg/kg; both, P o 0.05). A
placebo-adjusted decrease in HbA1c of 0.31% at week
12 was reported with canakinumab 10 mg/kg (P ¼
0.038), and a reduction of 0.23% at week 4 was found
with canakinumab 1.5 mg/kg (P ¼ 0.011).
Implications: The ﬁndings from this study suggest
that IL-1β blockade after single-dose administration of
canakinumab at 1.5 and 10 mg/kg provided sustained
suppression of hsCRP levels for 12 weeks in patients with
T2DM. ClinicalTrials.gov identiﬁer: NCT00900146.
(Clin Ther. 2014;36:1625–1637) & 2014 The Authors.
Published by Elsevier HS Journals, Inc.
Key words: canakinumab, high-sensitivity C-reac-
tive protein, interleukin-1β, pharmacodynamics, phar-
macokinetics, type 2 diabetes mellitus.
INTRODUCTION
Chronic poor glycemic control leads to the develop-
ment of cardiovascular complications in patients with
type 2 diabetes mellitus (T2DM).1 Most clinical
studies use morbidity and all-cause mortality as
parameters to assess cardiovascular outcomes in1625
Clinical Therapeuticspatients with T2DM. However, the use of surrogate
biomarkers such as high-sensitivity C-reactive protein
(hsCRP), interleukin (IL)-6, and ﬁbrinogen can pro-
vide a clearer understanding of the early inﬂammatory
changes at the subclinical level in response to the drug
effect, thus providing additive value in the assessment
of cardiovascular risk in patients with T2DM.
Although hsCRP is not a validated biomarker for
cardiovascular disease as yet, a meta-analysis con-
ducted by the Emerging Risk Factors Collaboration
Centre2 reported that each 1-SD increase in hsCRP
was associated with an increase in vascular risk at
least as great as that associated with an SD increase in
either blood pressure or cholesterol. Furthermore, in
multiple statin trials, hsCRP predicted vascular risk as
accurately as did on-treatment levels of low-density
lipoprotein cholesterol (LDL-C).3–7 Findings from
previously reported prospective cohort studies suggest
that patients with hsCRP of Z2 mg/L were at high
risk for cardiovascular diseases. PROVE-IT (Pravas-
tatin or Atorvastatin Evaluation and Infection Ther-
apy)4 and A-to-Z (Aggrastat-to-Zocor Trial)5 used a
cutoff criterion of hsCRP o2 mg/L and reported a
clinically meaningful relationship between the
reduction in hsCRP and a concurrent decrease in the
risk for cardiovascular disease. Similarly, in a
subgroup analysis from the JUPITER (Justiﬁcation
for the Use of Statins in Primary Prevention: An
Intervention Trial Evaluating Rosuvastatin) trial,
Ridker et al7 reported that reductions in both LDL-
C to o70 mg/dL and hsCRP to o2 mg/L were
independently associated with a lower cardiovascular-
events rate in healthy individuals with healthy choles-
terol levels. Moreover, the JUPITER study reported
that a reduction in hsCRP to o1.0 mg/L was associ-
ated with further reductions in events rates independent
of the achieved LDL-C levels.
Canakinumab, a human immunoglobulin (Ig) G1
monoclonal anti–IL-1β antibody of the IgG1/k iso-
type, competitively prevents IL-1β binding to IL-1
receptors. Canakinumab targets the IL-1β–dependent
inﬂammation pathway, thereby reducing the levels of
hsCRP and other inﬂammatory cardiovascular bio-
markers.8 IL-1β plays an important role in the
pathophysiology of autoinﬂammatory diseases such
as cryopyrin-associated periodic syndromes, speciﬁ-
cally Muckle-Wells syndrome and familial cold auto-
inﬂammatory syndrome, systemic juvenile idiopathic
arthritis, adult and juvenile rheumatoid arthritis, and1626gouty arthritis.9 Furthermore, IL-1β blockade has
been shown to improve β-cell function and to prevent
or delay the destruction of β cells and worsening of
diabetes in patients with T2DM.10 However, there is
limited evidence regarding the use of canakinumab in
patients with T2DM. This article describes the
pharmacokinetic (PK) and pharmacodynamic (PD)
data from a study that assessed the efﬁcacy and
tolerability of canakinumab in patients with T2DM.
PD data include the measurements of hsCRP as well
as total IL-1β (free and canakinumab–IL-1β complex)
serum concentrations, which are surrogate markers of
drug activity. We also report the change in hemoglo-
bin (Hb) A1c levels and tolerability in patients
with T2DM.PATIENTS AND METHODS
Study Design
This multicenter, randomized, double-blind, pla-
cebo-controlled, single-dose study of canakinumab
versus placebo was conducted in patients with
T2DM on a stable daily dose of metformin. The study
was conducted at 15 centers across Germany, the
United States, and Russia. The study was conducted
according to the ethical principles of the Declaration
of Helsinki. The study protocol and all amendments
were reviewed and approved by an independent ethics
committee or institutional review board. Written
informed consent was requested from all eligible
patients before randomization. This study is registered
with EUDRACT No. 2007-003729-26 and Clinical-
Trials.gov Identiﬁer NCT00900146.
In this study, 5 dose levels of canakinumab versus
placebo were evaluated in 4 cohorts. This study was
initially designed with 1 small cohort (cohort 1, 15
patients randomized 2:1 to active treatment:placebo)
for an initial tolerability evaluation using a single
intravenous dose (2-hour infusion) of canakinumab
0.3 mg/kg, followed by a cohort of 90 patients (cohort
2, 90 patients randomized 1:1 to active treatment:
placebo) who received a single intravenous dose of
canakinumab 10 mg/kg or placebo. Subsequently, on
the basis of the 1-month postdose data from cohort 2,
the study continued with the evaluation of the re-
sponse to lower doses. In cohort 3, 96 patients were
randomized to receive either 0.1, 0.3, or 1.5 mg/kg of
canakinumab or placebo (1:1:1:1 randomization). In
cohort 4 (n ¼ 30), patients were randomized (2:1,Volume 36 Number 11
A. Noe et al.active treatment:placebo) to receive either canakinu-
mab 0.03 mg/kg or placebo.
Patients in cohort 1 were on a stable dose of 500
mg/d of metformin, whereas all other patients were on
a stable dose of Z850 mg/d of metformin. Metformin
was the only oral antidiabetic agent allowed in
this study.
Inclusion and Exclusion Criteria
Men and women aged 18 to 70 years with a
conﬁrmed diagnosis of T2DM for at least 6 months,
stable body weight (5 kg) within 3 months before
screening, a body mass index of 25 to 40 kg/m2,
HbA1c levels between 7% and 9.5% inclusive, and on
stable dose of metformin monotherapy for at least 3
months before the screening visit were eligible to
participate in this study. The key exclusion criteria
included a history of type 1 diabetes or secondary
types of diabetes; complications of diabetes (ketoaci-
dosis); severe diabetic nephropathy or renal disease
with impaired glomerular ﬁltration rate; any active
infection or laboratory evidence of neutropenia (neu-
trophil count below the normal range); myocardial
infarction, unstable angina, or congestive heart failure
(New York Heart Association functional class III or
IV) in the preceding 6 months; and treatment with any
other antidiabetic agent, except metformin monother-
apy. Patients with any of the following laboratory
abnormalities at baseline were excluded: alanine
aminotransferase or aspartate aminotransferase 42
times the upper limit of normal, serum creatinine
Z1.5 times the upper limit of normal, proteinuria
Z1 g/d, and/or hsCRP Z10 mg/L.
Assessments
PK Measurements
Blood samples were collected just before drug
administration (0 hour), at 2 hours, and on days 2,
14, 28, 56, 84, and 168 after administration to
measure serum canakinumab concentrations and to
assess the PK parameters. Serum canakinumab con-
centrations were measured using competitive ELISA,
with a lower limit of quantiﬁcation (LLOQ) of 100
ng/mL. PK parameters including CL of drug from the
serum, Vd during the terminal elimination phase, t½,
Cmax, and Tmax were characterized using noncom-
partmental analysis by WinNonlin Professional ver-
sion 5.2 (Pharsight Corporation, Mountain View,
California).November 2014PD Measurements
IL-1β
Total IL-1β (sum of free and canakinumab bound)
was determined in the serum at 0 and 2 hours and on
days 2, 14, 28, 56, 84, and 168 after administration
using a commercially available sandwich ELISA
method (Quantikine HS kit; R&D Systems Inc,
Minneapolis, Minnesota), with an LLOQ of 0.5 pg/
mL. The drug CL and ligand production and elimi-
nation CL were estimated by nonlinear mixed-effects
modeling (NONMEM; Icon plc, Dublin, Ireland)
using the drug-ligand–binding model described pre-
viously by Chakraborty et al.9
hsCRP
At baseline, hsCRP was measured at a local
laboratory, together with a central laboratory, to
enable the timely inclusion of patients into the study.
HsCRP levels were assessed at baseline and at weeks
4, 8, 12, and 24 by immunonephelometry using the
BNII System nephelometer (Siemens Healthcare Diag-
nostics Inc, Deerﬁeld, Illinois) at the central labora-
tory. The hsCRP concentrations were determined with
an intra-assay precision of 2.3% to 4.4%, an inter-
assay precision of 2.1% to 5.7%, and an LLOQ of
0.020 mg/dL.
HbA1c
The screening HbA1c sample for inclusionary pur-
poses was analyzed at a local laboratory in each of the
cohorts to enable the timely enrollment of patients.
However, samples were sent to a central laboratory
for uniformity of assessment and ranges during the
study. HbA1c levels were assessed at baseline and at
weeks 4, 12, 18, and 24.
Tolerability Assessments
Tolerability assessments consisted of collecting all
adverse events (AEs) and serious AEs and assessing
their severity and relationship to the study drug. The
regular monitoring of hematology, blood chemistry,
and urinalysis were performed at local laboratories.
Vital signs, 12-lead ECG, physical condition, and
weight were also assessed.
Statistical Analysis
The primary efﬁcacy variable included PD effect of
canakinumab on HbA1c levels (cohorts 2, 3, and 4).
The secondary variables included assessments of PK1627
Clinical Therapeuticsand PD biomarkers, total serum canakinumab–IL-1β
complex concentrations, and hsCRP levels. Tolerabil-
ity was assessed throughout the study.
The tolerability of the initial dose of canakinumab
was assessed in 15 patients with T2DM in cohort 1.
This sample size ensured 83% power to detect an
absolute difference of 60% in adverse event (AE) rate
between the active and placebo groups at an α level of
0.10 using a 1-sided Fisher exact test. The remaining
cohorts were the basis for the assessments of efﬁcacy
and PD effect of canakinumab in patients with
T2DM. In the largest cohort of this study (cohort
2), 90 patients were randomized 1:1 to receive either
placebo or canakinumab 10 mg/kg with a 90%
likelihood of detection of a signiﬁcant difference (each
at an α level of 0.025) in HbA1c in canakinumab-
treated patients at week 4. A minimum sample size of
40 completing patients per treatment group would
provide 75% power to detect a 0.5% underlying
difference (absolute difference) in HbA1c between
treatments, which is generally considered as the lower
limit of clinical relevance in HbA1c reduction. Blinded
partial HbA1c data from cohort 2 suggested that the
variability at week 4 was considerably lower than was
the original statistical assumption and was 0.5%
(absolute unit). On the basis of the revised assumption
of variability, the sample size of 20 per treatment
group in cohort 3 would ensure 80% power to detect
a signiﬁcant difference in change from baseline in HbA1c
between one of the active groups and placebo at a 1-
sided α level of 0.05, if the true difference were 0.4% or
greater. In cohort 4, 30 patients would need to be
enrolled to ensure that at least 27 patients would
complete the trial. At sample sizes of 18 and 9 complet-
ing patients in the 0.03-mg/kg dose and placebo groups,
respectively, cohort 4 had 80% probability of detecting
a signiﬁcant difference in change from baseline in HbA1c
between the active-treatment and placebo groups at a 1-
sided α level of 0.05, if the true difference were 0.6% or
greater. The primary goal of cohort 4 was, however, to
characterize the effect of a very low dose instead of
hypothesis testing. All statistical evaluations were per-
formed using SAS statistical software (SAS Institute Inc,
Cary, North Carolina).
All randomized patients who received the study
drug were included in the tolerability analysis. All
randomized patients who received the study drug and
had data available from at least 1 postbaseline assess-
ment were included in the PD data analysis as the1628intent-to-treat population. The per-protocol popula-
tion included patients who completed the study up to
day 28 without a major protocol deviation. All
patients with evaluable PK data were included in the
PK data analysis.
Canakinumab PK parameters were determined by
the noncompartmental and compartmental modeling
methods using a PK binding model, and further details
are described elsewhere by Chakraborty et al.9 PK
parameters were analyzed using descriptive statistics
such as mean, SD, and %CV, and minimum and
maximum. hsCRP and biomarkers (IL-1β) were
logarithm-transformed (base e) before analysis to
normalize the skewed data. The difference between
each dose level of canakinumab and placebo was
back-transformed to give point estimates. The hsCRP
levels were analyzed using the ANCOVA model, with
treatment as a ﬁxed effect and baseline as a covariate
at 95% CIs. The corresponding P values are also
presented. The changes in HbA1c from baseline to
weeks 4, 12, 18, and 24 were assessed separately using
repeated-measures analysis, with treatment as a ﬁxed
effect and day as a repeated factor within the patient.
Safety data were summarized using descriptive statis-
tics by treatment cohort and dose. Because the sample
size of cohort 2 was clearly greater than those of the
other cohorts, an exploratory analysis was performed
in this cohort to estimate the number of patients with
hsCRP ofZ2 mg/L at baseline, and the corresponding
patients who achieved hsCRP o2 mg/L at weeks 4
and 12 postdose both in the 10-mg/kg and the placebo
groups, using noninferential statistics.
RESULTS
Patient Disposition and Baseline Characteristics
A total of 231 patients with T2DM were enrolled,
of whom 222 (cohort 1, 10 active treatment and 5
placebo; cohort 2, 44 active treatment and 45 placebo;
cohort 3, 68 active treatment and 24 placebo, and
cohort 4, 18 active treatment and 8 placebo) com-
pleted the study. The major reasons for study dis-
continuation were withdrawal of consent (3 patients)
and loss to follow-up (2 patients) (Table I).
Patients' demographic and clinical characteristics at
baseline were comparable across the treatment groups
(Table II). The mean ages of the groups ranged
between 52 and 57 years, and 490% were white.
Some imbalances between the cohorts with respect to
sex and duration of T2DM were noted. The 0.3-mg/Volume 36 Number 11
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November 2014kg dose group in cohort 3 had a higher percentage of
female patients (70.8%). The median duration of
T2DM was shorter in the 1.5- and 0.03-mg/kg dose
groups (3.0 and 3.8 years, respectively) and was
longest (9.6 years) in the placebo group in cohort 1.
Median hsCRP values at screening ranged from 1.8
(0.1 mg/kg, cohort 3) to 3.2 mg/L (0.03 mg/kg, cohort
4). The median daily doses of metformin ranged from
1000 to 2000 mg (mean daily dose, 1060.0–
1788.9 mg).Pharmacokinetic Properties
Exposure to canakinumab was dose proportional;
systemic CLs across groups were comparable. There
was no indication of accelerated CL from the termi-
nal phases of the concentration compared with the
time proﬁles that would suggest the formation of
antibody against canakinumab. Serum concentra-
tions of canakinumab at various time points after
single-dose intravenous administration are presented
in Figure 1.
After single-dose intravenous injection, canakinu-
mab reached a Cmax of 0.9 to 244 mg/mL at a median
time (Tmax) of 2 to 4 hours. The mean CL rate ranged
from 0.094 to 0.128 mL/h/kg across all doses, and the
mean apparent Vd ranged from 38 to 88 mL/kg in
patients with T2DM. With the exception of the
lowest-dose cohort (0.03 mg/kg) (216 hours), the
mean t½ of canakinumab ranged from 413 hours
(17 days) to 612 hours (26 days). PK parameters
calculated using noncompartmental analyses are sum-
marized in Table III.Pharmacodynamic Properties
IL-1β
Total canakinumab and total IL-1β concentration
data were available from 145 patients in the active-
treatment groups. The total IL-1β concentrations in
serum were increased after single-dose intravenous
administration in patients with T2DM (Figure 2),
reﬂecting binding of canakinumab to serum IL-1β
and slow CL of the IL-1β–antibody complex. The
mean (range) drug CL, free ligand CL, and ligand
production rates were 0.26 (0.1–1.45) L/day, 10.02
(7.65–15.01) L/day, and 6.84 (3.52–16.88) ng/day,
respectively. As expected, the free ligand CLs were
greater than were the antibody CLs.1629
Table II. Baseline demographic and clinical characteristics of the patients in this study of the pharmacokinetic properties of canakinumab
(randomized set).
Cohort 1 Cohort 2 Cohort 3 Cohort 4
Cohorts 3
and 4
Characteristic
Canakinumab
0.3 mg/kg
(n ¼ 10)
Placebo
(n ¼ 5)
Canakinumab
10 mg/kg
(n ¼ 45)
Placebo
(n ¼ 45)
Canakinumab
0.1 mg/kg
(n ¼ 25)
Canakinumab
0.3 mg/kg
(n ¼ 24)
Canakinumab
1.5 mg/kg
(n ¼ 23)
Canakinumab
0.03 mg/kg
(n ¼ 20) Placebo (n ¼ 34)
Demographic
Age, y
Mean 53.0 52.0 57.1 57.5 53.9 55.0 55.1 53.9 55.1
Range 43–67 45–63 30–70 35–69 40–69 39–69 34–68 32–67 38–68
Sex, no. (%)
Female 6 (60.0) 3 (60.0) 21 (46.7) 14 (31.1) 13 (52.0) 17 (70.8) 14 (60.9) 10 (50.0) 18 (52.9)
Male 4 (40.0) 2 (40.0) 24 (53.3) 31 (68.9) 12 (48.0) 7 (29.2) 9 (39.1) 10 (50.0) 16 (47.1)
White race, no. (%) 9 (90.0) 4 (80.0) 42 (93.3) 43 (95.6) 23 (92.0) 23 (95.8) 22 (95.7) 19 (95.0) 31 (91.2)
Clinical
BMI, kg/m2
Mean 31.2 30.7 30.7 30.8 32.6 31.6 32.5 30.4 32.8
Range 26–40 27–35 25–39 25–39 26–41 25–39 26–38 26–37 27–40
Group, no. (%)
o30 kg/m2 5 (50.0) 2 (40.0) 21 (46.7) 17 (37.8) 6 (24.0) 10 (41.7) 7 (30.4) 9 (45.0) 16 (47.1)
Z30 kg/m2 5 (50.0) 3 (60.0) 24 (53.3) 28 (62.2) 19 (76.0) 14 (58.3) 16 (69.6) 11 (55.0) 18 (52.9)
Duration of T2DM, y
Median 5.4 9.6 7.3 5.1 5.6 7.3 3.0 3.8 5.6
Range 1.6–27.0 4.6–13.0 0.7–24.0 0.3–21.0 1.4–13.6 1.2–20.8 0.7–15.3 0.6–13.9 0.8–21.9
HbA1c, mean, % 8.0 7.1 7.9 7.8 7.6 7.4 7.7 7.6 7.7
hsCRP, mg/L
Median No data
collected
No data
collected
2.3 2.0 1.8 2.0 2.4 3.2 2.5
Range — — 0.25–9.81 0.48–8.85 0.31–6.46 0.42–8.66 0.86–13.80 0.56–9.61 0.20–8.83
Metformin dose, mg/d
Median 1000 1000 1500 1000 1700 1850 1700 1500 2000
Range 500–2000 500–1700 850–3000 850–2550 1000–3000 1000–3000 850–3000 1000–2000 1000–3000
BMI, body mass index; HbA1c hemoglobin A1c; hsCRP, high-sensitivity C-reactive protein; T2DM, type 2 diabetes mellitus.
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A. Noe et al.hsCRP
The time course of the median change in hsCRP
levels over 24 weeks is presented in Figure 3A. A
signiﬁcant dose-related reduction in hsCRP was ob-
served at week 4, with greater reductions with higher
canakinumab doses compared with placebo (41%,
45%, 70%, and 74% with 0.1, 0.3, 1.5, and 10
mg/kg, respectively; all, P o 0.05) (Figure 3B). The
corresponding median changes in hsCRP values from
baseline to week 4 were 0.2, 0.5, 1.5, and 1.7
mg/L, respectively. The reduction in hsCRP was
maintained up to week 12 with the 2 highest dosesTable III. Summary of key pharmacokinetic (PK) parame
means (%CV) unless otherwise specified.
Cohort 1 Cohort 2
Parameter
Canakinumab
0.3 mg/kg
(n ¼ 9)
Canakinumab
10 mg/kg
(n ¼ 44)
Canaki
0.1 m
(n ¼
Cmax, mg/mL 8.4 (23) 244 (33) 2.6
Tmax, median, h 4 4 4
Vd, mL/kg 71 (16) 85 (24) 61
CL, mL/h/kg 0.094 (13) 0.099 (29) 0.116
t½, h 521 (13) 612 (21) 413
November 2014of canakinumab (49% with 1.5 mg/kg and 60%
with 10 mg/kg; both, P o 0.05), and the corres-
ponding median changes in hsCRP levels from base-
line were 0.8 and 1.3 mg/L, respectively.
At baseline, 60% (27/45) patients and 46.7% (21/
45) patients had hsCRP values of Z2 mg/L in the 10-
mg/kg and placebo groups, respectively (Table IV).
After single-dose administration of 10 mg/kg canaki-
numab, 21 of the 27 patients (77.8%) with a baseline
hsCRPZ2 mg/L achieved hsCRPo2 mg/L compared
with 3 of 21 patients (14.3%) in the placebo group at
week 4. This reduction in hsCRP to o2 mg/L wasters of canakinumab (PK data set). Data are given as
Cohort 3 Cohort 4
numab
g/kg
24)
Canakinumab
0.3 mg/kg
(n ¼ 19)
Canakinumab
1.5 mg/kg
(n ¼ 23)
Canakinumab
0.03 mg/kg
(n ¼ 17)
(29) 8.2 (18) 41.0 (24) 0.9 (25)
4 4 2
(39) 66 (25) 88 (92) 38 (19)
(70) 0.095 (28) 0.116 (121) 0.128 (23)
(36) 494 (26) 572 (19) 216 (40)
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Figure 3. A, Time course of median high-sensitivity C-reactive protein (hsCRP) levels after single-dose
administration of canakinumab (ITT population). B, Mean (SD) changes in hsCRP after single-
dose administration of canakinumab (ITT population). *P o 0.05 versus placebo. Data on the
10-mg/kg dose were available only for weeks 4 and 12. ITT, intent-to-treat population using the
last observation carried forward.
Clinical Therapeuticsmaintained in 17 of 27 patients (63.0%) treated with
10 mg/kg of canakinumab at week 12.
Change in HbA1c Levels
Single-dose administration of canakinumab 10 mg/
kg was associated with a placebo-adjusted decrease in
HbA1c of 0.31% (P ¼ 0.038) at week 12. Single-dose
administration of canakinumab 1.5 mg/kg was asso-
ciated with a statistically signiﬁcant, albeit clinically
irrelevant, reduction in HbA1c compared with placebo
(–0.23%; P ¼ 0.011) at week 4. In general, numeri-
cally moderate but statistically nonsigniﬁcant decreases1632from baseline to weeks 4 and 12 in HbA1c were seen in
all patients after single-dose intravenous administration
of 5 different doses of canakinumab. The adjusted
mean changes from baseline in HbA1c, by treatment
and visit, are presented in Table V.
Tolerability
Overall, the incidences of reported AEs were
similar between the active-treatment and placebo
groups. Patients reporting any AE were 1 (10%) with
0.3 mg/kg versus 2 (40%) with placebo in cohort 1;
18 (40.0%) with 10 mg/kg versus 14 (31.1%) withVolume 36 Number 11
Table IV. Rates of patients achieving hsCRP o2 mg/L with canakinumab versus placebo. Data are given as
number (%) of patients.
Time Point
Canakinumab 10 mg/kg
(n ¼ 45) Placebo (n ¼ 45)
Baseline
Z2 mg/L 27 (60.0) 21 (46.7)
o2 mg/L 18 (40.0) 24 (53.3)
Week 4 (hsCRP o2 mg/L) 21/27 (77.8) 3/21 (14.3)
Week 12* (hsCRP o2 mg/L) 17/27 (63.0) 3/21 (14.3)
*At week 12 in canakinumab 10 mg/kg group, data for one patient was missing.
A. Noe et al.placebo in cohort 2; 8 (32.0%) with 0.1 mg/kg, 6
(25.0%) with 0.3 mg/kg, 4 (17.4%) with 1.5 mg/kg,
and 7 (29.2%) with placebo in cohort 3; and 10
(50.0%) with 0.03 mg/kg versus 2 (20.0%) with
placebo in cohort 4. In cohort 1, 1 patient in the
active-treatment group had inﬂuenza and 2 patients
each in the placebo group had ocular hyperemia and
headache. In cohort 2, the most common AEs re-
ported were infections and infestations (nasopharyng-
itis and cystitis), gastrointestinal disorders (diarrhea),
nervous system disorders (headache), and investiga-
tion (increased blood triglycerides and increased li-
pase). The most frequently reported events in cohorts
3 and 4 were infections and infestations (nasophar-
yngitis, bronchitis, and urinary tract infection); respi-
ratory, thoracic, and mediastinal disorders (nasal
congestion); gastrointestinal disorders (diarrhea and
nausea); cardiac disorders (ventricular extra systoles);
nervous system disorders (headache and dizziness), and
skin and subcutaneous tissue disorders (rash). The
incidence of AEs did not seem to be dose related and
was similar to that in the placebo group. Most AEs
were mild in intensity and were considered not related
to the study drug. No apparent trend was observed over
the dose range of single-dose administration of canaki-
numab. In the study, 3 patients reported serious AEs: 1
patient who received canakinumab 10 mg/kg experi-
enced an intestinal polyp, and 2 patients in the placebo
group in cohort 2 reported myocardial infarctions.
DISCUSSION
The results from this multicenter, double-blind, placebo-
controlled, single-dose administration of canakinumabNovember 2014or placebo in patients with T2DM on a stable dose of
metformin (median dose range, 1000–2000 mg/d)
suggest that there were no tolerability issues with
canakinumab. The clearance of canakinumab was time
and dose independent, and canakinumab use was
associated with a dose-dependent reduction in hsCRP
levels at week 4, which was sustained for 12 weeks in
the higher-dose groups (1.5 and 10 mg/kg). Both
canakinumab 1.5 and 10 mg/kg doses showed a
numerically moderate, albeit clinically irrelevant, reduc-
tion in HbA1c in patients with T2DM receiving met-
formin (baseline HbA1c, 7.4%–7.9%).
Canakinumab displayed the typical PK properties of
an IgG1-type antibody, that is, low CL and low Vd,
resulting in a long mean t½ ranging from 17 to 26 days
across doses, which is consistent with the 21-day
terminal elimination half-life determined for a typical
IgG1 antibody.9 The mean t½ was longer with the 1.5
and 10 mg/kg doses. Systemic CLs across dose groups
were comparable, suggesting that within the adminis-
tered dose range, the PK proﬁle was dose proportional.
There was no evidence of accelerated CL from the
terminal phases of the concentration–time proﬁles that
would suggest the formation of antibody against cana-
kinumab. The results from this study are consistent with
the previously reported data in healthy volunteers.9
Canakinumab binding to endogenous IL-1β neu-
tralizes the bioactive effect of IL-1β, thereby resulting
in the formation of a canakinumab–IL-1β complex.9
The CL rate of the canakinumab-IL-1β complex was
lower than that of the free ligand (IL-1β), leading to an
increase in the total serum IL-1β concentration,
suggesting the binding of IL-1β by canakinumab. This1633
Table V. Changes from baseline in hemoglobin A1c with canakinumab versus placebo (intent-to-treat population). Data are given as %.
Cohort 2 Cohorts 3 and 4
Study Week
Canakinumab
10 mg/kg Placebo
Canakinumab
0.03 mg/kg
Canakinumab
0.1 mg/kg
Canakinumab
0.3 mg/kg
Canakinumab
1.5 mg/kg Placebo
Week 4
No. of patients 45 45 20 25 23 23 34
Baseline 7.88 (0.101) 7.84 (0.122) 7.61 (0.176) 7.62 (0.171) 7.44 (0.106) 7.68 (0.157) 7.72 (0.162)
Δ vs baseline, adjusted
mean (SE)
–0.38 (0.057) –0.26 (0.057) –0.13 (0.073) –0.25 (0.065) –0.30 (0.069) –0.47 (0.068) –0.24 (0.056)
Δ vs placebo
Mean (SE) –0.12 (0.080) — 0.10 (0.092) –0.01 (0.086) –0.06 (0.089) –0.23 (0.088) —
95% CI –0.28 to 0.04 — –0.08 to 0.29 –0.18 to 0.16 –0.24 to 0.11 –0.40 to –0.05 —
P 0.142 — 0.258 0.890 0.487 0.011 —
Week 12
No. of patients 44 42 20 25 23 23 33
Baseline 7.87 (0.103) 7.87 (0.127) 7.61 (0.176) 7.62 (0.171) 7.41 (0.105) 7.68 (0.157) 7.69 (0.165)
Δ vs baseline, adjusted
mean (SE)
–0.46 (0.102) –0.15 (0.105) –0.15 (0.132) –0.04 (0.118) –0.43 (0.124) –0.59 (0.124) –0.32 (0.103)
Δ vs placebo
Mean (SE) –0.31 (0.147) — 0.17 (0.168) 0.28 (0.157) –0.11 (0.162) –0.27 (0.161) —
95% CI –0.60 to –0.02 — –0.16 to 0.50 –0.03 to 0.60 –0.43 to 0.21 –0.59 to 0.05 —
P 0.038 — 0.309 0.073 0.507 0.097 —
Week 18
No. of patients 45 45 20 21 22 23 33
Baseline 7.88 (0.101) 7.84 (0.122) 7.61 (0.176) 7.39 (0.144) 7.47 (0.108) 7.68 (0.157) 7.75 (0.164)
Δ vs baseline, adjusted
mean (SE)
–0.29 (0.101) –0.02 (0.101) –0.11 (0.128) –0.08 (0.126) –0.22 (0.123) –0.40 (0.120) –0.19 (0.101)
Δ vs placebo
Mean (SE) –0.27 (0.142) — 0.08 (0.163) 0.11 (0.162) –0.03 (0.159) –0.21 (0.156) —
95% CI –0.55 to 0.02 — –0.24 to 0.40 –0.21 to 0.43 –0.34 to 0.29 –0.52 to 0.10 —
P 0.066 — 0.630 0.512 0.862 0.179 —
Week 24
No. of patients 43 45 20 24 20 21 33
Baseline 7.89 (0.104) 7.84 (0.122) 7.61 (0.176) 7.57 (0.172) 7.40 (0.111) 7.70 (0.168) 7.74 (0.167)
Δ vs baseline, adjusted
mean (SE)
–0.26 (0.121) –0.01 (0.118) 0.32 (0.177) 0.27 (0.162) –0.18 (0.178) –0.39 (0.173) –0.12 (0.138)
Δ vs placebo
Mean (SE) –0.25 (0.169) — 0.44 (0.225) 0.40 (0.213) –0.06 (0.226) –0.26 (0.221) —
95% CI –0.58 to 0.09 — 0.00 to 0.89 –0.02 to 0.82 –0.51 to 0.39 –0.70 to 0.18 —
P 0.149 — 0.052 0.065 0.796 0.238 —
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A. Noe et al.apparent binding may have led to the blockage of
downstream events of IL-1β signaling, including IL-1β
production, IL-1β pathway–related gene activation (ie,
elevation of acute phase proteins such as serum
amyloid A and hsCRP), and mobilization of neutro-
phils and platelets from bone marrow. Similar results
were observed in other populations (cryopyrin-asso-
ciated periodic syndromes, gouty arthritis, rheumatoid
arthritis, and healthy subjects).9
Inﬂammation plays a role in the development and
progression of atherosclerosis and β-cell dysfunction.
HsCRP, an acute-phase inﬂammatory biomarker, has
the potential to identify individuals at high risk for
both ﬁrst and recurrent vascular events even in the
absence of hyperlipidemia and other major vascular
risk factors.11 In a recent study, hsCRP was found to
be a vascular-events predictor at least as strong as
blood pressure and cholesterol levels.2 In the present
study, the antiinﬂammatory activity of canakinumab
was evaluated by measuring the reduction in hsCRP
levels over 24 weeks. The baseline median hsCRP
levels of patients enrolled in this study ranged from
1.8 to 3.2 mg/L. Treatment with canakinumab across
different doses was associated with statistically
signiﬁcant reductions in hsCRP of –0.2 to –1.7 mg/L
versus baseline at the ﬁrst time point at which hsCRP
was measured (week 4) (all, P o 0.05). These
reductions were sustained for 12 weeks in patients
who received canakinumab 1.5 and 10 mg/kg (–0.8
and –1.3 mg/L, respectively, vs a baseline median
2.4 mg/L). Furthermore, results from an explo-
ratory analysis suggested that a single dose of 10
mg/kg canakinumab was associated with reductions in
hsCRP to a clinically relevant value of o2.0 mg/L at
weeks 4 and 12. This evidence is promising and suggests
that long-term therapy with canakinumab may reduce
cardiovascular risk. However, further studies with can-
akinumab needs to be investigated to afﬁrm the sustained
reduction in hsCRP levels in chronic diseases.
Few studies have evaluated the relationship be-
tween hsCRP and HbA1c levels in patients with
T2DM.12,13 In this study, a statistically signiﬁcant,
albeit clinically irrelevant, reductions in HbA1c were
sustained for 12 weeks in patients who received
canakinumab 10 mg/kg, for 4 weeks in patients who
received the 1.5-mg/kg dose. The mean HbA1c values
at baseline in the 4 cohorts ranged between 7.1% and
8.0%, with no apparent correlation with hsCRP levels
(baseline median hsCRP of 1.8–3.2 mg/L), probablyNovember 2014due to the relatively satisfactory glycemic control. This
single-dose study was designed to describe the PK
properties of canakinumab and was not powered to
ascertain the clinical correlation between hsCRP and
HbA1c levels.
A single injection of canakinumab across evaluated
doses was found to be well tolerated in patients with
T2DM. The AEs reported were similar between the
canakinumab and placebo groups. The safety proﬁle,
including the incidence of infection, was consistent
with those from other published clinical trials of
canakinumab in patients with cryopyrin-associated
periodic syndromes, rheumatoid arthritis, and gouty
arthritis.14–18
The prolonged effect canakinumab on ablating the
acute-phase inﬂammatory response suggests that
quarterly dosing is feasible. Whether this regimen,
once applied chronically in diseases in which modu-
lation of hsCRP response may predict efﬁcacy, trans-
lates into a clinically meaningful response is being
evaluated in other trials. CANTOS (Canakinumab
Anti-inﬂammatory Thrombosis Outcome Study) is an
ongoing study exploring the efﬁcacy of quarterly
dosing of canakinumab to test the hypothesis of
inﬂammation as a cause of atherothrombosis.
CANTOS is the ﬁrst randomized trial aimed to
determine whether the long-term inhibition of IL-1β
with canakinumab (50, 150, or 300 mg administered
subcutaneously every 3 months) compared with pla-
cebo reduces the rates of recurrent cardiovascular
events, deﬁned as nonfatal myocardial infarction,
nonfatal stroke, or cardiovascular death, among stable
patients who have had a myocardial infarction and
who remain at elevated cardiovascular risk due to
increased hsCRP (Z2 mg/L) despite usual care,
including statin therapy.11 The prolonged effects on
reducing hsCRP levels for 12 weeks with no
signiﬁcant adverse ﬁndings support the feasibility of
the ongoing CANTOS trial. If positive, CANTOS will
not only afﬁrm the inﬂammatory hypothesis of
atherothrombosis but also provide an entirely novel
cytokine-based therapy for the secondary prevention
of cardiovascular disease.11
CONCLUSIONS
The PK and PD properties of canakinumab, an anti-
IL-1β monoclonal antibody, in patients with T2DM
were consistent with the results reported previously in
other populations such as cryopyrin-associated1635
Clinical Therapeuticsperiodic syndromes, rheumatoid arthritis, gouty ar-
thritis, and healthy subjects.9 A single dose of
canakinumab 1.5 and 10 mg/kg was associated with
a strong and sustained suppression of hsCRP levels
and a moderate but sustained reduction in HbA1c in
patients with T2DM for 12 weeks.ACKNOWLEDGMENTS
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